Rural America's Prescribing Problem

Medicare Part D prescribing looks very different depending on where you live. States with large rural populations consistently show higher opioid prescribing rates, more brand-name drug use, and higher per-patient costs. The urban-rural divide in prescribing isn't just a statistical curiosity — it has real consequences for patient outcomes and taxpayer costs.

The Opioid Geography

The states with the highest average opioid prescribing rates are disproportionately rural:

Why Rural Prescribing Differs

1. Fewer specialists, more generalists — Rural areas rely heavily on Nurse Practitioners and Family Practice providers. These generalists handle a wider range of conditions, including chronic pain, leading to higher opioid prescribing rates.
2. Occupational injuries — Rural economies are dominated by farming, mining, logging, and manufacturing — physically demanding jobs with high injury rates that generate legitimate pain management needs.
3. Pharmacy access — Rural patients often have fewer pharmacy options, potentially limiting access to newer (and sometimes cheaper) medications.
4. Older populations — Rural America skews older. Medicare Part D beneficiaries in rural areas tend to have more chronic conditions requiring more medications.
5. Historical prescribing culture — Some regions developed high-prescribing patterns during the late 1990s/early 2000s opioid expansion and haven't fully corrected.

The Cost Implications

Higher opioid rates don't just affect patient health — they affect taxpayer costs. States with the highest opioid prescribing rates also tend to have higher per-patient drug costs, partly because opioid-heavy practices often coincide with:

• More brand-name prescribing (less access to generic alternatives)
• Higher emergency utilization from drug interactions and overdoses
• Longer treatment durations and dose escalation

What the Data Can't Tell Us

Medicare Part D data captures prescribing patterns but not patient outcomes. A high opioid rate might reflect appropriate care for a patient population with high injury rates — or it might reflect over-prescribing. Without linking to patient outcomes data (emergency visits, overdose rates, mortality), we can't definitively distinguish between the two.

What we can say is that the geographic variation is persistent and significant — the same states led in opioid prescribing five years ago and still lead today. Whatever is driving these patterns isn't going away on its own.